La vendita allo scoperto per Himalaya Shipping dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Himalaya Shipping. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Himalaya Shipping (NYSE:HSHP) Azioni, Report sulle vendite allo scoperto

Himalaya Shipping Ltd is an independent dry bulk company that focuses on owning and operating its Newcastlemax dry bulk carriers.

Himalaya Shipping Ltd

HILL & SMITH HOLDINGS by Hill & Smith Holdings Plc.

Hill & Smith PLC

News

Guidance

CVS's Q3 Results Won't Meet Wall Street's Expectations; Plans To Back Away From Current 2024 Guidance

<p>HC Wainwright &amp; Co.  analyst Heiko Ihle   reiterates DRDGold (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DRD#NYSE">DRD</a>) with a Buy and maintains $13.25 price target.</p>


Price Target

Reiteration

Analyst Ratings

HC Wainwright & Co. Reiterates Buy on DRDGold, Maintains $13.25 Price Target

Management

CVS Naming Caremark President David Joyner As Its New CEO

<p>HC Wainwright &amp; Co.  analyst Heiko Ihle   reiterates Avino Silver &amp; Gold Mines (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/ASM#AMEX">ASM</a>) with a Buy and maintains $1.5 price target.</p>


HC Wainwright & Co. Reiterates Buy on Avino Silver & Gold Mines, Maintains $1.5 Price Target

Biotech

Large Cap

Health Care

General

The European Medicines Agency's Committee For Medicinal Products For Human Use Has Adopted A Positive Opinion, Recommending Approval Of Novo Nordisk's Alhemo (Concizumab) As The First Once-Daily Subcutaneous Prophylactic Treatment For People Aged 12 Years Or Older With Hemophilia A Or B With Inhibitors.

<p>HC Wainwright &amp; Co.  analyst Heiko Ihle   reiterates First Majestic Silver (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AG#NYSE">AG</a>) with a Buy and maintains $8.5 price target.</p>


HC Wainwright & Co. Reiterates Buy on First Majestic Silver, Maintains $8.5 Price Target

<p>The combined companies for the trailing twelve months have generated $235 million in revenue, increasing approximately&nbsp;25%&nbsp;quarter-over-quarter.</p>


BTTR

Better Choice Expects Combined 2025 Pro Forma Basis Revenue And EBITDA To Be Approximately +$270M, And +$10M, Respectively

Better Choice Says Continues To Make Progress Towards Closing Of Its Acquisition Of SRx Health Solutions; Expects Transaction To Close In Late Q4 Of This Year Or Early Q1 Of 2025

<p>Needham  analyst Ami Fadia   reiterates Neumora Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NMRA#NASDAQ">NMRA</a>) with a Buy and maintains $23 price target.</p>


NMRA

Needham Reiterates Buy on Neumora Therapeutics, Maintains $23 Price Target

<p>Based on sales trends and order intake in recent years, it expects further market share gains with domestic Chinese OEMs in the coming years.</p>
<p>With the seasonally strong fourth quarter remaining of the year, it reaffirms&nbsp;guidance of around 9.5-10.0% adjusted operating margin for 2024, but to be at the low end of this range.</p>
<p>&nbsp;</p>


Autoliv Now Expects Full Year 2024 Organic Sales Growth To Be 1% Instead Of Previously Expected 2% Due To Unfavorable Market Mix Development

<p>Regions Finl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RF#NYSE">RF</a>) reported quarterly earnings of $0.57 per share which beat the analyst consensus estimate of $0.53 by 7.55 percent. This is a 16.33 percent increase over earnings of $0.49 per share from the same period last year.  The company reported quarterly sales of $1.87 billion which beat the analyst consensus estimate of $1.80 billion by 3.78 percent.  This is a 0.54 percent increase over sales of $1.86 billion the same period last year.</p>


Earnings

Earnings Beats

Regions Finl Q3 Adj $0.57 Beats $0.53 Estimate, Sales $1.87B Beat $1.80B Estimate

<p>HC Wainwright &amp; Co.  analyst Patrick Trucchio   reiterates Alnylam Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) with a Buy and maintains $400 price target.</p>


ALNY

HC Wainwright & Co. Reiterates Buy on Alnylam Pharmaceuticals, Maintains $400 Price Target

<p>Autoliv (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALV#NYSE">ALV</a>) reported quarterly earnings of $1.84 per share which missed the analyst consensus estimate of $1.95 by 5.64 percent.  The company reported quarterly sales of $2.56 billion which beat the analyst consensus estimate of $2.53 billion by 0.89 percent.  This is a 1.58 percent decrease over sales of $2.60 billion the same period last year.</p>


Earnings Misses

Autoliv Q3 2024 Adj EPS $1.84 Misses $1.95 Estimate, Sales $2.56B Beat $2.53B Estimate

<p>HC Wainwright &amp; Co.  analyst Amit Dayal   reiterates Gevo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GEVO#NASDAQ">GEVO</a>) with a Buy and maintains $14 price target.</p>


GEVO

HC Wainwright & Co. Reiterates Buy on Gevo, Maintains $14 Price Target

<p>Needham  analyst Ami Fadia   reiterates Avadel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVDL#NASDAQ">AVDL</a>) with a Buy and maintains $22 price target.</p>


Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share

AVDL

Needham Reiterates Buy on Avadel Pharmaceuticals, Maintains $22 Price Target

<p>Needham  analyst Mayank Tandon   maintains WNS (Hldgs) (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WNS#NYSE">WNS</a>) with a Buy and lowers the price target from $70 to $60.</p>


Needham Maintains Buy on WNS (Hldgs), Lowers Price Target to $60

<p>Needham  analyst Kyle Peterson   reiterates Equifax (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EFX#NYSE">EFX</a>) with a Buy and maintains $350 price target.</p>


Needham Reiterates Buy on Equifax, Maintains $350 Price Target

<p>Needham  analyst Mike Matson   downgrades Boston Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>) from Buy to Hold and maintains the price target from $86 to $86.</p>


Downgrades

Needham Downgrades Boston Scientific to Hold, Maintains Price Target to $86

<p><a href="https://www.reuters.com/technology/apples-new-iphone-sales-china-jump-20-first-3-weeks-counterpoint-says-2024-10-18/" title="https://www.reuters.com/technology/apples-new-iphone-sales-china-jump-20-first-3-weeks-counterpoint-says-2024-10-18/">https://www.reuters.com/technology/apples-new-iphone-sales-china-jump-20-first-3-weeks-counterpoint-says-2024-10-18/</a></p>


Tech

AAPL

Reported Earlier, Apple's New iPhone Sales In China Rose 20% In First 3 Weeks

<p>EV <a href="https://www.benzinga.com/news/24/10/41223011/rivians-production-guidance-cut-spurred-by-miscommunication-with-atlanta-based-supplier-resulting-in">startup</a> <strong>Rivian Automotive</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIVN#NASDAQ">RIVN</a>) said on Thursday that it will launch its Halloween software update starting Oct. 18, complete with spooky features and car costumes.</p>
<p><strong>What Happened: </strong>The company announced the update in a video posted on social media platform X featuring actor <strong>David Hasselhoff </strong>who starred in the Knight Rider series.</p>
<p><figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"><br />
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true"><p lang="en" dir="ltr">An iconic duo reunited <a href="https://twitter.com/DavidHasselhoff?ref_src=twsrc%5Etfw">@DavidHasselhoff</a>.⁰<br /><br />The countdown is on. Our Halloween software update arrives after the clock strikes midnight (local). Spooky features will be available for a limited time. <a href="https://t.co/hdKV0z4WIC">pic.twitter.com/hdKV0z4WIC</a></p>
<p>&mdash; Rivian (@Rivian) <a href="https://twitter.com/Rivian/status/1846945663860572411?ref_src=twsrc%5Etfw">October 17, 2024</a></p></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
<p></p></figure></p>
<p>One of the car costumes available with the update is inspired by Knight Rider. The costume will alter the Rivian&#8217;s interior display system and the exterior lightbar on Gen 2 R1 vehicles will cascade a red beam to replicate the experience of K.I.T.T, the robotic automobile that featured in the series.</p>
<p>There are also other car costumes available with the update, inspired by iconic and classic vehicles from pop culture, such as one inspired by the time machine in Universal Pictures and Amblin Entertainment's Back to the Future, in addition to a spooky option. </p>
<p>The haunted Rivian car costume has eight different sound effects and three different color themes to choose from ranging between purple, yellow, red, and green. The interior display screen will feature static and ghosts to increase the spooky feeling when the vehicle is parked with the costume. </p>
<p><strong>Besides Costumes: </strong>Besides costumes, Rivian&#8217;s new update changes pedestrians on the driver display to zombies and bicyclists and motorcyclists into headless horsemen. </p>
<p>Vehicle owners can also play multiple spooky chirp sounds, including one resembling the owl. </p>
<p>However, the spooky features will only be available for a limited time until November 4, the company warned. Additionally, <a href="https://www.benzinga.com/news/24/08/40574576/rivian-or-lucid-which-of-the-two-loss-making-ev-startups-is-solving-cash-burn">both the vehicle</a> and the Rivian mobile app must be updated to their latest versions for the features, it added.</p>
<p><em>Check out more of Benzinga&#8217;s Future Of Mobility coverage by&nbsp;</em><a href="https://www.benzinga.com/topic/mobility" target="_blank" rel="noreferrer noopener"><em>following this link</em></a>.</p>
<p><strong>Read More:</strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/news/24/10/41324450/elon-musk-says-spacexs-next-generation-starlink-satellites-will-be-so-big-that-only-starship-can-lau" target="_blank" rel="noreferrer noopener">Elon Musk Says SpaceX's Next-Generation Starlink Satellites Will Be ‘So Big That Only Starship Can Launch Them'</a></strong></li>
</ul>
<p><em>Photo courtesy: Rivian</em></p>


RIVN

Trick Or Treat: Rivian Rolls Out Spooky Halloween Update Featuring Car Costumes, Creepy Chirps

Himalaya Shipping Ltd. declares $0.04 dividend

In a report released on June 20, Peter M. E. Christensen from Cleaves Securities maintained a Hold rating on Himalaya Shipping Ltd. (HSHP – Researc...

Cleaves Securities Remains a Hold on Himalaya Shipping Ltd. (HSHP)

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p>While <a href="https://investorplace.com/stock-types/blue-chip-stocks/">blue chip stocks</a> are always a good investment portfolio idea, I suggest some smart diversification. And one of the best ways that I know to diversify is to buy highly rated stocks under $10.</p>



<p>Stocks under $10 may not sound interesting, but these names can be a strategic move for anyone wanting to diversify and improve their portfolios. </p>



<p>While cautious investors will associate lower-priced stocks with higher risk, the Portfolio Grader can help you find some outstanding choices to round out a portfolio.</p>



<p>It&rsquo;s important to remember that stocks under $10, when included in a portfolio of blue-chip equities, can expose you to smaller companies with high growth potential. And diversification is important because if you have a falling segment, your gains from other sectors can help you mitigate your losses.</p>



<p>The Portfolio Grader can help you find stocks that are priced low, not because they are struggling but because they are an excellent opportunity. Stocks under $10 could be priced that way because of restructuring or because the company is in an emerging industry.</p>



<p>By evaluating stocks based on momentum, analyst sentiment, revenue growth and earnings performance, you have a better chance of choosing quality stocks under $10 for your portfolio. These seven names are a good place to start.</p>



<h2>Summit Therapeutics (SMMT)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/07/bio1600-300x169.jpg" alt="MRNA Stock Will Continue Its Slump, but a $25 It Will Be a Great Buy"><div>Source: Shutterstock</div></div><p><strong>Summit Therapeutics</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/smmt-stock-quote/"><strong>SMMT</strong></a>) is a biopharmaceutical company that works on the discovery, development and commercialization of therapies for unmet medical needs.</p>



<p>The company currently has two Phase 3 trials underway with its lead candidate, ivonescimab, an investigational bispecific antibody to treat non-small cell lung cancer.</p>



<p>The company recently raised <a href="https://www.smmttx.com/wp-content/uploads/2024/06/2024_PR_0602_Fundraise-and-Expansion-of-Summit-License-Territories-for-Ivonescimab-_-FINAL.pdf">$200 million</a> from an institutional investor for 22.2 million shares of SMMT stock. It plans to use the money to advance the development of ivonescimab, with the goal of completing Phase 3 trials and submitting the treatment to regulators for approval.</p>



<p>That money will be added to the <a href="https://www.smmttx.com/pressrelease/summit-therapeutics-reports-financial-results-and-operational-progress-for-the-first-quarter-ended-march-31-2024/">$157 million</a> the company had on hand at the end of the first quarter, in which it spent $46.2 million on operating expenses. The company doesn&rsquo;t have an income stream yet, so it posted a loss of $34 million, or 5 cents per share, for the first quarter.</p>



<p>SMMT stock is up 196% in 2024 and gets a &ldquo;B&rdquo; rating in the Portfolio Grader.</p>



<h2>Annexon (ANNX)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/07/biotech1600d-300x169.jpg" alt="Image of two scientists in lab coats studying results in a lab. best biotech stocks to buy"><div>Source: Shutterstock</div></div><p><strong>Annexon</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/annx-stock-quote/"><strong>ANNX</strong></a>) is a California-based bioscience company developing treatments for autoimmune, neurodegenerative, and ophthalmic diseases of the body, brain, and eye.</p>



<p>Its impressive pipeline includes a potential treatment for Guillain-Barre syndrome, a rare disorder in which the body&rsquo;s immune system is expected to report Phase 3 trials in the fourth quarter.</p>



<p>It also has Phase 2 trials for potential treatments for geographic atrophy, Huntington&rsquo;s disease and amyotrophic lateral sclerosis, otherwise known as ALS.</p>



<p><a href="https://ir.annexonbio.com/news-releases/news-release-details/annexon-reports-first-quarter-2024-financial-results-and-key">Earnings for the first quarter</a> included $21 million in research and development expenses and $7.6 million in administrative costs. The company has cash and cash equivalents of $264.9 million and expects to have enough money currently to fund operations into mid-2026.</p>



<p>ANNX stock is up 14% this year and gets a &ldquo;B&rdquo; rating in the Portfolio Grader.</p>



<h2>Aurora Cannabis (ACB)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/07/aurora-cannabis-stock-3-300x169.jpg" alt="aerial view of a cannabis plant in a pot. cannabis stocks"><div>Source: Shutterstock</div></div><p><strong>Aurora Cannabis</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/acb-stock-quote/"><strong>ACB</strong></a>) is a Canadian cannabis company that is considered a leading producer of medical cannabis in Canada.</p>



<p>The company has a variety of medical-use and adult recreational products, including flower products, vapes, edibles, concentrates and more.</p>



<p><a href="https://investorplace.com/industries/healthcare/cannabis/">Cannabis stocks</a> were a hot commodity in 2020 when there was an expectation that the Biden administration and a Democratic-controlled Congress would push through federal legalization of marijuana rather than leaving it to the states. </p>



<p>However, the Covid-19 pandemic and inflationary issues derailed those plans, and federal recreational use is still a pipe dream for Aurora investors.</p>



<p>However, the Justice Department is recommending that cannabis be reclassified from a Schedule 1 to a Schedule 3 drug, which would give marijuana stocks a boost.</p>



<p><a href="https://www.auroramj.com/press-releases/article/?id=123076">Aurora&rsquo;s financial results for the fourth quarter of fiscal 2024</a> (ending March 31) included $67.4 million in revenue, up 5% from the previous year. Medicinal cannabis made up a large part of that increase, as it was up 20% from last year, while adult recreational use was down 29%.</p>



<p>I expect the numbers for adult recreational cannabis to improve. ACB stock is up 15% this year and gets a &ldquo;B&rdquo; rating in the Portfolio Grader.</p>



<h2>Himalaya Shipping (HSHP)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/04/zim_shipping1600-2-300x169.png" alt="A large ULCV container ship underway, sails on open water fully loaded with containers and cargo - the ZIM San Francisco"><div>Source: ImagineStock / Shutterstock.com</div></div><p>Based in Bermuda,<strong> Himalaya Shipping</strong> (NYSE:<a href="https://investorplace.com/stock-quotes/hshp-stock-quote/"><strong>HSHP</strong></a>) is a new entrant into the shipping business. It just accepted delivery of its 12th dual-fueled dry bulk vessel from a Chinese shipyard, with each ship capable of transporting 210,000 in dead weight tonnage.</p>



<p>As new ships, the fleet of next-generation cargo ships can use liquefied natural gas for propulsion, reducing per-ton emissions by 60%. The company also started paying a monthly dividend in January, and plans to continue the practice that will be popular for income investors.</p>



<p>Earnings for the first quarter of 2024 included revenue of $23.6 million and net income of $2.5 million. Now that the fleet is fully operational, Himalaya Shipping should see those numbers improve.</p>



<p>HSHP stock is up 27% in 2024 and gets an &ldquo;A&rdquo; rating in the Portfolio Grader.</p>



<h2>Emergent BioSolutions (EBS)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/08/ebs-stock-1-300x169.jpg" alt="A mobile phone displays the website for Emergent Biosolutions (EBS)"><div>Source: T. Schneider / Shutterstock.com</div></div><p><strong>Emergent BioSolutions</strong> (NYSE:<a href="https://investorplace.com/stock-quotes/ebs-stock-quote/"><strong>EBS</strong></a>) is a biopharmaceutical company headquartered in Maryland. The company develops vaccines and antibody therapies for infectious diseases and to treat opioid overdoses.</p>



<p>The company has countermeasures to combat some of the most critical public health threats in the world, including smallpox, anthrax and botulism. It also makes a reactive skin decontamination lotion kit among other products.</p>



<p>Meanwhile, its pipeline includes potential treatments for Lassa fever, Ebola, and influenza.</p>



<p>The company is undoubtedly doing important work, and it&rsquo;s being well rewarded. <a href="https://investors.emergentbiosolutions.com/static-files/6f3b9a75-7d44-4585-a6b6-65c067219850">Revenues</a> in the first quarter were $300.4 million, up from $164.3 million in the same quarter a year ago. The company also posted a profit of $9 million after posting a loss of $186.2 million in the first quarter of 2023.</p>



<p>&nbsp;EBS stock is on a roll this year, up 169% so far. It gets a &ldquo;B&rdquo; rating in the Portfolio Grader.</p>



<h2>Reborn Coffee (REBN)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2021/09/coffee_1600-300x169.jpg" alt="NUZE Stock. A photo of a cup of coffee and some coffee beans and a towel on a wooden table. Coffee stocks"><div>Source: Evgeny Karandaev/ShutterStock.com</div></div><p><strong>Reborn Coffee</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/rebn-stock-quote/"><strong>REBN</strong></a>) is a specialty coffee maker. Coffee is one of the most popular drinks in the U.S., with an estimated <a href="https://www.statista.com/topics/9899/coffee-consumption-trends-in-the-united-states/">73%</a> of American consumers acknowledging being a coffee drinker. </p>



<p>It seems there&rsquo;s coffee for every pallet, including high-priced coffeehouse drinks to at-home drip coffee makers that give you a basic cup of joe.</p>



<p>Reborn Coffee is has only 14 locations, mostly in California. But it also offers a subscription service on its website, and makes whole-bean products, pour-over packs and cold brew packs.</p>



<p>It doesn&rsquo;t expect to stay small for long. Reborn announced an <a href="//www.pressviewer.com/profiles/investor/NewsPrint.asp?v=7&amp;b=2799&amp;ID=135032&amp;m=rl&amp;g=2317%27,%27LibDiv%27);">expansion</a> into China and Southeast Asia and plans to open a location in Abu Dhabi. It also has serious <a href="//www.pressviewer.com/profiles/investor/NewsPrint.asp?v=7&amp;b=2799&amp;ID=135157&amp;m=rl&amp;g=2317%27,%27LibDiv%27);">e-commerce</a> plans by making its products available on <strong>Amazon</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/amzn-stock-quote/"><strong>AMZN</strong></a>).</p>



<p>Earnings for the <a href="https://www.reborncoffee.net/news-events/press-releases/#b2iLibScrollTo">fourth quarter of 2023</a> included revenue of $1.8 million, up 109% from the same quarter a year ago. Full-year revenue was $6 million versus $3.2 million in 2022.</p>



<p>REBN stock is up 48% this year and gets a &ldquo;B&rdquo; rating in the Portfolio Grader.</p>



<h2>NuScale Power (SMR)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2024/03/smr1600-300x169.png" alt="Person holding smartphone with logo of US nuclear power company NuScale Power LLC on screen in front of website. Focus on phone display. Unmodified photo. SMR stock"><div>Source: T. Schneider / Shutterstock.com</div></div><p><strong>NuScale Power</strong> (NYSE:<a href="https://investorplace.com/stock-quotes/smr-stock-quote/"><strong>SMR</strong></a>) is an Oregon company that makes small modular light water nuclear reactors that are expected to help companies phase out coal-powered plants.</p>



<p>The company also is seeking approval for a proposal in Romania that would be the first European project to use small modular light nuclear reactor technology. The effort has $4 billion in commitments for U.S. financial institutions, and the company is hoping to get approval in 2025.</p>



<p>Such a deal would be a massive win for NuScale and its investors.</p>



<p>SMR stock, which has reactors that can provide power in nuclear plants, is under $10 now but probably won&rsquo;t be for long. It is currently up 190% in 2024 and gets a &ldquo;B&rdquo; rating in the Portfolio Grader.</p>



<p><em>On the date of publication, neither Louis&nbsp;Navellier nor the InvestorPlace Research Staff member primarily responsible for this article held (either directly or indirectly) any positions in the securities mentioned in this article.</em></p>
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
<p>The post <a href="https://investorplace.com/market360/2024/06/7-top-stocks-under-10-june-2024-edition/">7 Top Stocks Under $10: June 2024 Edition</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

7 Top Stocks Under $10: June 2024 Edition

In a report released on July 8, Peter M. E. Christensen from Cleaves Securities maintained a Hold rating on Himalaya Shipping Ltd. (HSHP – Research...

Comments

Himalaya Shipping

Vendite allo scoperto

Himalaya Shipping (NYSE:HSHP) Azioni, Report sulle vendite allo scoperto

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO